A 62-year-old female with a productive sputum was pointed out of a mass of 2.5 cm in diameter in left S4 with lymphadenopathy of station 10, 4, and 3 on computed tomographic scan, which were heterogeneously enhanced by radiocontrast agent. She was diagnosed with pulmonary adenocarcinoma and clinical stage IIIA (T1N2M0, N2-multistation). First-line induction therapy of cisplatin plus paclitaxel had been performed but failed to respond to the chemotherapy. Second-line induction therapy of gefitinib for 6 months had showed the shrinkage of the tumor and resulted in a down-stage (T1N0M0, IA). Positron emission topography revealed no abnormal accumulations of the primary tumor and the mediastinal lymph nodes. As salvage surgery, left upper lobectomy was performed and the pathology revealed negative findings of metastasis in lymph nodal station 4, 5, 6, 7, and 11 but in a positive in station 10. The viable cells in the tumor had been residual (Ef.2) and diagnosed with stage IIA (pT1N1M0). Detection test of epidermal growth factor receptor gene mutation showed a negative result. The patient obtained 5-year's long-term survival without metastasis and recurrence. The combination therapy of gefitinib-induction therapy followed by surgery for advanced lung cancer with N2-multistation would have an advantage of good outcome for such patient in the limited gefitinib-responded population as tailor-made therapies.
Introduction
Gefitinib (IRESSA TM , AstraZeneka, Osaka, Japan) is an orally active epidermal growth factor receptor (EGFR)-tyrosin kinase inhibitor (TKI) and was the first EGFR-targeted therapy to be approved for the treatment of non-small cell lung cancer (NSCLC) that failed to respond to chemotherapy. However, the effect of gefitinib as an induction therapy remains unclear, especially unknown in patients without EGFR gene mutations.
We report a dramatically responded case of gefitinibinduction therapy followed by surgical resection for the advanced lung cancer with N2-multistation, which case has been showing a more than 5-year long-term survival without metastasis and recurrence.
Case Report
A nonsmoker, 62-year-old female with a productive sputum was pointed out of abnormal shadow in the left lung field on X-ray film in July, 2006. The level of car-cinoembryonal antigen (CEA) was increased to be 329.4 ng/dl. She was admitted to our hospital and computed tomographic (CT) scanning of chest displayed a mass of 2.5 cm in diameter in S4 ( Fig. 1a ) and mediastinal lymphadenopathy of station 10, 4, and 3, which were heterogeneously enhanced by radiocontrast agent (Fig. 1b ). She was diagnosed with pulmonary adenocarcinoma by transbronchoscopic lung biopsy and with clinical stage IIIA and N2-multistation. Positron emission topography revealed abnormal accumulations of the mediastinal metastasis. In September, 2006, first-line induction therapy of cisplatin plus paclitaxel was performed in 2 cycles, but the effectiveness was evaluated in stable disease. As second-line induction therapy, oral administration of gefitinib (250 mg/day) had been started in November, 2006. After the 6 months treatment, the level of CEA had been dramatically decreased to be within normal limit, and the tumor had been shrunk in size of 10 mm by CT scan ( Fig. 2a ) and the lymphadenopathy of station 10, 4, and 3 had been reduced in size ( Fig. 2b ), which could be evaluated in partial response (reduction ratio is 72%). Positron emission topography revealed no abnormal accumulations of the primary tumor and the mediastinal lymph nodes. This case had dramatically responded to this gefitinib-induction therapy and downstaged to be The shrunk tumor was a 1 cm in diameter ( Fig. 3a ), but viable cells were observed in the residual tumor (Ef.2) ( Fig. 3b ). Eventually, she was diagnosed with stage IIA (pT1N1M0). A detection test of EGFR gene mutation 1) showed a negative result. As adjuvant therapy, combination of gemcitabine plus carboplatin was performed in 3 cycles. From September in 2007, as a maintenance therapy, oral administration of S-1 (80 mg in every 1 -28 days in 6 weeks) had been performed, even though cytotoxic events of diarrhea and elevation of serum bilirubin level, the dose-intensity had to decrease to be 37.5% of the initial dosage (40 mg in every 1 -14 days in 4 weeks).
We had continued the oral S-1 treatment for 2 years and completed in September, 2009. The level of CEA was normal and 1.2 ng/ml in August, 2011. She has been healthy without recurrence, metastasis, and elevation of level of CEA value for more than 5 years from the initial date of the first-line induction therapy for advanced IIIAstaged lung cancer.
Discussion
Gefitinib is the first targeted drug to be approved for advanced NSCLC that failed to respond to chemotherapy. It has a fairly effective antitumor activity in patients with tumors harboring EGFR gene mutations. However, the effect of gefitinib as a neoadjuvant therapy remains unclear, especially unknown in patients without EGFR gene mutations. In our case, as first-line induction therapy, we performed chemotherapy of paclitaxel plus carboplatin for the advanced lung cancer with N2-multistation (T1N2M0, stage IIIA), however, because of the failure in response of chemotherapy, as second-line induction therapy, oral administration of gefitinib had been performed for 6 months, the primary tumor and the mediastinal N2-multistations had been dramatically shrunk. As the advanced lung cancer had been downstaged, left upper lobectomy as salvage surgical resection was performed. The patient could obtain a good five years' long-term survival from gefitinib-induction therapy followed by surgery for advanced lung cancer with N2-multistation.
NSCLC patients with specific clinical features appear to have a greater likelihood of having a mutated form of EGFR. Analysis of 14 studies involving 2880 patients showed EGFR mutations occur more frequently in women than men (38% versus 10%), Asian than non-Asian patients (32% versus 7%), never-smokers than current or former smokers (47% versus 7%) and patients with adenocarcinoma histology than non-adenocarcinoma histology (30% versus 2%) 2) . On the other hand, even though our case was non-smoker, female, and Asian, the patient had been expected to response the gefitinib treatment but had the negative results by a postoperative detection test of EGFR gene mutation 1) . This discrepancy between the dramatic gefitinib-responder and EGFR gene mutationnegative result should be caused by the heterogeneity of the tumor consisting of EGFR mutation-positive and negative tumor cells. The EGFR-positive cancer cells might have resulted in apoptosis by gefitinib treatment and the EGFR-negative ones might have remained as viable cells, or which should be caused by the dependence on the accuracy of our used detection methods of EGFR gene mutation 1) .
Several prospective clinical trials of gefitinib or erlotinib for treatment of NSCLC patients with EGFR gene mutations have been done to date [3] [4] [5] [6] [7] [8] [9] [10] [11] . These trials have shown radiographic response rates ranging from 55% to 82% and a median progression-free survival (PFS) of 8.9 to 13.3 months. These values are three to four times those historically observed with platinum-based chemotherapy as a first-line treatment for advanced NSCLC. Recently, the role of gefitinib in first-line therapy for patients with known EGFR mutations was confirmed in the randomized Phase III Iressa Pan-Asia Study (IPASS) 12) . Gefitinib group demonstrated superior progression-free survival than carboplatin-paclitaxel group (HR: 0.74; 95% CI: 0.65 -0.85; P<0.0001) in the overall population. 
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Most importantly, the PFS of the subgroup of patients with EGFR mutations was significantly better than that of the overall population who received gefitinib alone (HR: 0.48; 95% CI: 0.36 -0.64; p<0.0001). Patients without EGFR mutations had detrimental effects from treatment with first-line gefitinib (HR: 2.86; 95% CI: 2.05 -3.86; p<0.0001). We reviewed on the combination therapy of gefitinib and surgery for advanced lung cancer, some outcomes have been reported; that is, induction therapy of advanced lung cancer harboring EGFR mutation [13] [14] [15] , surgical resection after neoadjuvant gefitinib treatment of lung adenocarcionoma without EGFR mutation 16) , and salvage surgery for advanced NSCLC after response to gefitinib 17) . However, these literatures referred to the results on short-or mid-term outcomes. There were no reports on the long-term outcomes such as our case.
Conclusion
We could obtain a successful case of good 5-year's long-term survival from gefitinib-induction therapy for advanced lung cancer with N2-multistation. A new combination therapy, that is, induction therapy of EGFR-TKI followed by surgery for advanced NSCLC, which would have an advantage of good outcome for such the limited gefitinib-responded patients in EGFR mutation-positive population as tailor-made therapies.
